PARP Inhibitor Pipeline Outlook Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight

DelveInsight's "PARP inhibitor Pipeline Insights 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the PARP inhibitor pipeline landscape. It covers the PARP inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the PARP inhibitor therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight's comprehensive PARP inhibitor Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ PARP inhibitor Pipeline Outlook Report- https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the PARP inhibitor Pipeline Report
• On 28 August 2025, AstraZeneca announced a study is a Phase I/IIa modular, open-label, multi-center study of AZD5335 administered either as monotherapy or in combination with other anti-cancer agents in participants with advanced solid malignancies.
• On 26 August 2025, Marc Dall'Era, MD conducted a phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
• On 26 August 2025, EMD Serono Research & Development Institute, Inc. announced a study is to measure the effect and safety of treatment with tuvusertib combined with either niraparib or lartesertib in participants with epithelial ovarian cancer and to assess any differences between tuvusertib monotherapy and combination therapy. The participants will previously have progressed while treated with a poly ADP ribose polymerase (PARP) inhibitor. The primary objectives of this study are to assess the effect of the treatment in terms of overall response, i.e. whether the tumor disappears, shrinks, remains unchanged, or gets worse and safety in terms of adverse events.
• DelveInsight's PARP inhibitor pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for PARP inhibitor treatment.
• The leading PARP inhibitor Companies such as TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics and others
• Promising PARP inhibitor Therapies such as Vismodegib, Atezolizumab, Olaparib Pill, AZD6738, JPI-547, Rucaparib, Durvalumab, Cisplatin and others.

Access DelveInsight's in-depth PARP inhibitor Pipeline Analysis for a closer look at promising breakthroughs @ PARP inhibitor Clinical Trials and Studies- https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

PARP inhibitor Emerging Drugs Profile
• Pamiparib: BeiGene
Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene's investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies.

The PARP inhibitor Pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of PARP inhibitor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PARP inhibitor Treatment.
• PARP inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• PARP inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PARP inhibitor market.

Get a detailed analysis of the latest innovations in the PARP inhibitor pipeline. Explore DelveInsight's expert-driven report today! @ PARP inhibitor Unmet Needs- https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

PARP inhibitor Companies
TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics and others.

PARP Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

PARP inhibitor Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Download DelveInsight's latest report to gain strategic insights into upcoming PARP inhibitor Therapies and key Developments @ PARP inhibitor Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the PARP inhibitor Pipeline Report
• Coverage- Global
• PARP inhibitor Companies- TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics and others
• PARP inhibitor Therapies- Vismodegib, Atezolizumab, Olaparib Pill, AZD6738, JPI-547, Rucaparib, Durvalumab, Cisplatin and others.
• PARP inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• PARP inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight's exclusive PARP inhibitor Pipeline Report-access it now! @ PARP inhibitor Emerging Drugs and Major Companies- https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. PARP Inhibitors: Overview
4. Structure
5. Mechanism of Action
6. Pipeline Therapeutics
7. Comparative Analysis
8. Therapeutic Assessment
9. Assessment by Product Type
10. Assessment by Stage and Product Type
11. Assessment by Route of Administration
12. Assessment by Stage and Route of Administration
13. Assessment by Molecule Type
14. Assessment by Stage and Molecule Type
15. PARP Inhibitors - DelveInsight's Analytical Perspective
16. In-depth Commercial Assessment
17. PARP Inhibitors companies' collaborations, Licensing, Acquisition -Deal Value Trends
18. PARP Inhibitors Collaboration Deals
19. Company-Company Collaborations (Licensing / Partnering) Analysis
20. Company-University Collaborations (Licensing / Partnering) Analysis
21. Late Stage Products (Phase III)
22. Comparative Analysis
23. Pamiparib: BeiGene
24. Product Description
25. Research and Development
26. Product Development Activities
27. Drug profiles in the detailed report.....
28. Mid Stage Products (Phase II)
29. Comparative Analysis
30. Drug Name: Company Name
31. Product Description
32. Research and Development
33. Product Development Activities
34. Drug profiles in the detailed report.....
35. Pre-clinical and Discovery Stage Products
36. Comparative Analysis
37. Drug Name: Company Name
38. Product Description
39. Research and Development
40. Product Development Activities
41. Drug profiles in the detailed report.....
42. Inactive Products
43. Comparative Analysis
44. PARP Inhibitors Key Companies
45. PARP Inhibitors Key Products
46. PARP Inhibitors- Unmet Needs
47. PARP Inhibitors- Market Drivers and Barriers
48. PARP Inhibitors- Future Perspectives and Conclusion
49. PARP Inhibitors Analyst Views
50. PARP Inhibitors Key Companies
51. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.